REG - Allergy Therapeutics - Appointment of Shaun Furlong to Board of Directors

Allergy TherapeuticsAnnouncement

11/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240311:nRSK2469Ga&default-theme=true

RNS Number : 2469G  Allergy Therapeutics PLC  11 March 2024

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

 

Appointment of Dr. Shaun Furlong to Board of Directors

 

11 March 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial
biotechnology company specialising in allergy vaccines, is pleased to announce
the appointment of Shaun Furlong as an Executive Director of the Company, with
effect from 8 March 2024.

 

Shaun was appointed as the Group's Chief Financial Officer (CFO) in August
2023, having previously served as Group Financial Controller since April 2022.
He brings significant financial experience, having held senior finance roles
within blue-chip companies across multiple sectors, including Legal &
General, Hastings Direct, Volution Group and American Express. Shaun is a
Fellow of the Institute of Chartered Accountants in England and Wales and
holds a PhD in polymer chemistry from the University of Sussex.

 

Peter Jensen, Chairman of Allergy Therapeutics, commented: "Shaun has proven
himself to be an invaluable asset to the Company since his appointment as
Group Financial Controller and more recently since his appointment as Chief
Financial Officer last year. Given his professionalism, strong financial
acumen and range of experience, I have no doubt that he will be an important
contributor to the Board."

 

Commenting on his appointment, Shaun Furlong said: " I am delighted to take
on an expanded leadership role as an Executive Director and look forward to
working alongside the other members of the Board."

 

Additional Information in respect of the AIM Rules:

Shaun Antony Furlong, aged 48, holds an interest in 1,500 ordinary shares in
the Company. In the previous five years, Shaun was a director of SAF
Management Services Limited. The Company confirms that there is no other
information in relation to Shaun's appointment that is required to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules
for Companies.

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAJMMPTMTMBBFI